LMAT stock forecast, quote, news & analysis

Key Takeaways

• LeMaitre Vascular shares have rebounded approximately 6.5% over the last 30 days, recovering from the mid-$88 level in late June back above $102.
• The stock remains roughly 7% below its late-April levels near $110, reflecting a broader pullback across small- and mid-cap medical device names during the second quarter.
• Q1 2026 results delivered 11% sales growth, 42% EPS expansion, and a 350-basis-point gross margin improvement, with management raising full-year guidance.
• Q2 2026 earnings are scheduled for August 4, 2026, and analyst consensus points to EPS of $0.81 on revenue near $71.5 million.
• Analysts maintain a Moderate Buy consensus rating with an average 12-month price target of approximately $112.60, though insider selling activity has been notable in recent months.

Current Market Snapshot

LeMaitre Vascular (LMAT) enters early August trading near $102, having climbed off a late-June trough around $88.61. The roughly 6.5% gain over the past 30 days suggests that buyers are stepping in after the stock's second-quarter retreat from its April peak near $118. Trading volumes have remained moderate, and the stock's 50-day moving average, recently hovering near $97, has provided a technical floor during the recent recovery. Broader healthcare sector sentiment remains mixed as investors weigh the impact of interest rate expectations and hospital capital spending trends on medical device companies. Against this backdrop, LMAT's relatively low beta of 0.52 and strong balance sheet — with $367 million in cash and securities at the end of Q1 — have attracted defensive positioning from institutional investors, who now hold roughly 85% of outstanding shares.

LeMaitre Vascular (LMAT) Business Overview and Competitive Position

LeMaitre Vascular is a specialty medical device company focused on developing, manufacturing, and marketing disposable and implantable devices for the treatment of peripheral vascular disease, a condition affecting over 200 million people worldwide. Headquartered in Burlington, Massachusetts, the company's product portfolio spans anastomotic clips, biologic and synthetic vascular grafts, carotid shunts, embolectomy catheters, valvulotomes, and cardiac and vascular patches. The company also offers human tissue cryopreservation services. Its core customer base consists of vascular surgeons, with additional reach into cardiac surgery, general surgery, and neurosurgery. LeMaitre sells directly in 31 countries and distributes products in additional markets, giving it a diversified geographic footprint. The company differentiates itself through a specialized focus on open vascular surgery — a niche largely underserved by larger medtech competitors — alongside disciplined pricing power and consistent margin expansion. Its Artegraft biologic graft product line has emerged as a growth standout, expanding 36% in Q1 2026 driven by the international launch.

Recent Developments Driving LMAT

Several developments have shaped investor sentiment around LMAT in recent weeks. On July 14, the company announced that Q2 2026 results will be released on August 4, 2026, setting the stage for what analysts expect to be continued double-digit revenue growth. The Q1 2026 report, released on May 5, showed sales of $66.6 million (+11% YoY), EPS of $0.68 (+42%), and a gross margin of 72.7% — a 350-basis-point expansion driven by higher average selling prices and manufacturing efficiencies. All three geographic regions posted record sales, with EMEA leading at +20%. Management raised full-year 2026 guidance to approximately $280 million in revenue and EPS of $3.00 at the midpoint, reflecting confidence in the product pipeline and direct sales expansion. The company also paid a quarterly dividend of $0.25 per share in June and has an active $100 million share repurchase authorization in place through February 2027. On the analyst front, firms including Citizens JMP and Barrington Research have reiterated positive ratings, with price targets ranging from $104 to $127. However, insider selling has drawn attention: directors and executives sold approximately 54,000 shares over the last 90 days, collectively exceeding $5.9 million in value. The company also participated in the Jefferies Global Healthcare Conference in early June, reinforcing its strategic narrative around Artegraft international expansion and the RestoreFlow Allograft rollout.

Trending AI Robots

For investors seeking data-driven approaches to stock selection, Tickeron's Trending AI Robots page showcases a curated selection of top-performing AI trading bots. Tickeron offers hundreds of AI-driven trading bots that actively trade thousands of tickers across multiple strategies and timeframes, but only the most relevant and consistently high-performing bots appear in this featured section. Each bot operates with a distinct methodology — ranging from short-term momentum plays to longer-duration swing strategies — allowing traders to find approaches that align with their individual risk tolerance and objectives. Performance metrics, win rates, and trade histories are displayed transparently, enabling users to evaluate bot effectiveness before committing capital. Exploring the Trending AI Robots section can help traders identify systematic, algorithm-driven opportunities in stocks like LMAT and beyond.

2026 Outlook and What Investors Should Watch

Looking ahead, the immediate catalyst for LMAT is the Q2 2026 earnings report scheduled for August 4. Investors will scrutinize revenue growth consistency, gross margin sustainability above 72%, and any updates to the full-year guidance. The Artegraft product line — projected to generate $10 million in 2026 sales versus $4 million in 2025 — remains a central growth narrative, particularly as Health Canada approval paves the way for a second-half launch. The RestoreFlow Allograft expansion into Germany and Ireland also represents a promising incremental revenue stream. On the operational side, the company's plan to expand its direct sales force to 170–180 representatives by year-end signals ongoing investment in commercial infrastructure. Macroeconomic factors, including currency fluctuations given meaningful European exposure, hospital capital equipment budgets, and the interest rate environment, will influence sentiment. Competitive pressures in the vascular surgery niche remain relatively contained given LeMaitre's specialized positioning, though execution on M&A — management has indicated 2–3 term sheets year-to-date — could reshape the growth profile. With a forward P/E near 32 and consensus analyst price targets implying upside from current levels, the stock's trajectory in the second half of 2026 will likely hinge on sustained organic growth delivery and disciplined capital allocation.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations